130 related articles for article (PubMed ID: 11311792)
21. Neurotensin receptors and dopamine transporters: effects of MPTP lesioning and chronic dopaminergic treatments in monkeys.
Goulet M; Morissette M; Grondin R; Falardeau P; Bédard PJ; Rostène W; Di Paolo T
Synapse; 1999 Jun; 32(3):153-64. PubMed ID: 10340626
[TBL] [Abstract][Full Text] [Related]
22. Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys.
Chen Q; Andersen AH; Zhang Z; Ovadia A; Cass WA; Gash DM; Avison MJ
Exp Neurol; 1999 Jul; 158(1):63-75. PubMed ID: 10448418
[TBL] [Abstract][Full Text] [Related]
23. The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys.
Parent A; Lavoie B; Smith Y; Bédard P
Adv Neurol; 1990; 53():111-6. PubMed ID: 1978512
[TBL] [Abstract][Full Text] [Related]
24. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
[TBL] [Abstract][Full Text] [Related]
25. Alterations in pallidal neuronal responses to peripheral sensory and striatal stimulation in symptomatic and recovered parkinsonian cats.
Rothblat DS; Schneider JS
Brain Res; 1995 Dec; 705(1-2):1-14. PubMed ID: 8821727
[TBL] [Abstract][Full Text] [Related]
26. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Clarke CE; Boyce S; Sambrook MA; Stahl SM; Crossman AR
Naunyn Schmiedebergs Arch Pharmacol; 1988 Jul; 338(1):35-8. PubMed ID: 2907097
[TBL] [Abstract][Full Text] [Related]
27. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions.
Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R
Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350
[TBL] [Abstract][Full Text] [Related]
28. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.
Goldberg JA; Boraud T; Maraton S; Haber SN; Vaadia E; Bergman H
J Neurosci; 2002 Jun; 22(11):4639-53. PubMed ID: 12040070
[TBL] [Abstract][Full Text] [Related]
29. α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.
Zhang D; McGregor M; Bordia T; Perez XA; McIntosh JM; Decker MW; Quik M
Mov Disord; 2015 Dec; 30(14):1901-1911. PubMed ID: 26573698
[TBL] [Abstract][Full Text] [Related]
30. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy.
Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y
Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399
[TBL] [Abstract][Full Text] [Related]
31. Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys.
Raz A; Frechter-Mazar V; Feingold A; Abeles M; Vaadia E; Bergman H
J Neurosci; 2001 Feb; 21(3):RC128. PubMed ID: 11157099
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of metabotropic glutamate receptor 1alpha in globus pallidus and substantia nigra of parkinsonian monkeys.
Kaneda K; Tachibana Y; Imanishi M; Kita H; Shigemoto R; Nambu A; Takada M
Eur J Neurosci; 2005 Dec; 22(12):3241-54. PubMed ID: 16367790
[TBL] [Abstract][Full Text] [Related]
33. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
34. Reduced cortical innervation of the subthalamic nucleus in MPTP-treated parkinsonian monkeys.
Mathai A; Ma Y; Paré JF; Villalba RM; Wichmann T; Smith Y
Brain; 2015 Apr; 138(Pt 4):946-62. PubMed ID: 25681412
[TBL] [Abstract][Full Text] [Related]
35. Glial cell line-derived neurotrophic factor-levodopa interactions and reduction of side effects in parkinsonian monkeys.
Miyoshi Y; Zhang Z; Ovadia A; Lapchak PA; Collins F; Hilt D; Lebel C; Kryscio R; Gash DM
Ann Neurol; 1997 Aug; 42(2):208-14. PubMed ID: 9266731
[TBL] [Abstract][Full Text] [Related]
36. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia.
Mitchell IJ; Boyce S; Sambrook MA; Crossman AR
Brain; 1992 Jun; 115 ( Pt 3)():809-24. PubMed ID: 1628204
[TBL] [Abstract][Full Text] [Related]
37. Involvement of the subthalamic nucleus in glutamatergic compensatory mechanisms.
Bezard E; Boraud T; Bioulac B; Gross CE
Eur J Neurosci; 1999 Jun; 11(6):2167-70. PubMed ID: 10336685
[TBL] [Abstract][Full Text] [Related]
38. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.
Aubert I; Guigoni C; Håkansson K; Li Q; Dovero S; Barthe N; Bioulac BH; Gross CE; Fisone G; Bloch B; Bezard E
Ann Neurol; 2005 Jan; 57(1):17-26. PubMed ID: 15514976
[TBL] [Abstract][Full Text] [Related]
39. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography.
Robertson RG; Clarke CA; Boyce S; Sambrook MA; Crossman AR
Brain Res; 1990 Oct; 531(1-2):95-104. PubMed ID: 2289139
[TBL] [Abstract][Full Text] [Related]
40. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.
Brownell AL; Canales K; Chen YI; Jenkins BG; Owen C; Livni E; Yu M; Cicchetti F; Sanchez-Pernaute R; Isacson O
Neuroimage; 2003 Oct; 20(2):1064-75. PubMed ID: 14568476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
